INO Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 2.50%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Inovio Pharmaceuticals Insider Trading History Chart

Inovio Pharmaceuticals Share Price & Price History

^$4.06

▲ +0.09 (2.27%)

As of 11/21/2024 01:00 AM ET

Days: 30 | 90 | 365

917 Trades… Zero Losses?

From Insiders Exposed | Ad

As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”

Go here to see how you can start accessing these opportunities today

Inovio Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/13/2023	David B Weiner	Director	Sell	40	$165.60	$6,624.00	6,320
2/27/2023	David B Weiner	Director	Sell	81	$184.32	$14,929.92	6,279
8/11/2022	David B Weiner	Director	Sell	82	$383.04	$31,409.28	6,198
7/20/2022	Simon X. Benito	Director	Sell	13	$324.00	$4,212.00	522
3/16/2022	Simon X. Benito	Director	Sell	13	$455.04	$5,915.52
3/14/2022	David B Weiner	Director	Sell	28	$460.80	$12,902.40
1/19/2022	Simon X. Benito	Director	Sell	13	$614.88	$7,993.44

Download Our Tesla Ebook For Free

From DTI | Ad

Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.

To claim your copy free of charge simply follow this link.

SEC Filings (Institutional Ownership Changes) for Inovio Pharmaceuticals (NASDAQ:INO)

26.79% of Inovio Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Inovio Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/19/2024	Barclays PLC	34,003	$0.20M	0.0%	+282.6%	0.130%
11/16/2024	Geode Capital Management LLC	621,631	$3.59M	0.0%	+6.7%	2.395%
11/15/2024	Barclays PLC	34,003	$0.20M	0.0%	+282.6%	0.131%
11/15/2024	Jane Street Group LLC	18,192	$0.11M	0.0%	-17.4%	0.070%
11/15/2024	Wellington Management Group LLP	65,633	$0.38M	0.0%	N/A	0.253%
11/15/2024	State Street Corp	490,662	$2.84M	0.0%	+11.7%	1.890%
11/15/2024	Atom Investors LP	17,747	$0.10M	0.0%	N/A	0.068%
11/14/2024	MetLife Investment Management LLC	15,167	$88K	0.0%	+129.1%	0.058%
11/13/2024	BNP Paribas Financial Markets	5,681	$33K	0.0%	+177.0%	0.022%
11/13/2024	FMR LLC	27,261	$0.16M	0.0%	+370.1%	0.105%
10/3/2024	SG Americas Securities LLC	12,286	$71K	0.0%	N/A	0.047%
8/15/2024	Susquehanna Fundamental Investments LLC	99,991	$0.81M	0.0%	-6.4%	0.386%
8/15/2024	The Manufacturers Life Insurance Company	10,169	$82K	0.0%	N/A	0.039%
8/9/2024	Renaissance Technologies LLC	410,566	$3.32M	0.0%	-8.8%	1.585%
8/9/2024	Dimensional Fund Advisors LP	74,858	$0.61M	0.0%	N/A	0.289%
8/8/2024	Cornercap Investment Counsel Inc.	22,712	$0.18M	0.0%	N/A	0.088%
8/8/2024	American Century Companies Inc.	31,565	$0.26M	0.0%	+62.2%	0.122%
8/1/2024	Rhumbline Advisers	38,494	$0.31M	0.0%	+5,943.0%	0.149%
7/26/2024	Signature Estate & Investment Advisors LLC	10,876	$88K	0.0%	N/A	0.042%
7/26/2024	Bank of New York Mellon Corp	81,835	$0.66M	0.0%	N/A	0.316%
5/16/2024	Jacobs Levy Equity Management Inc.	16,497	$0.23M	0.0%	-98.6%	0.071%
5/15/2024	Price T Rowe Associates Inc. MD	12,499	$0.17M	0.0%	-91.7%	0.053%
5/10/2024	Vanguard Group Inc.	1,594,385	$22.13M	0.0%	-91.9%	6.822%
5/7/2024	Susquehanna Fundamental Investments LLC	106,791	$1.48M	0.1%	N/A	0.457%
5/3/2024	GSA Capital Partners LLP	79,979	$1.11M	0.1%	-97.9%	0.342%
4/10/2024	Green Alpha Advisors LLC	36,417	$0.51M	0.4%	-91.9%	0.156%
2/9/2024	Keystone Financial Group	122,737	$63K	0.0%	+11.7%	0.540%
2/8/2024	Vanguard Personalized Indexing Management LLC	115,361	$59K	0.0%	+5.6%	0.507%
1/5/2024	Green Alpha Advisors LLC	451,725	$0.23M	0.2%	-20.8%	0.165%
11/13/2023	Acadian Asset Management LLC	460,200	$0.18M	0.0%	N/A	0.172%
11/9/2023	Prime Capital Investment Advisors LLC	138,972	$54K	0.0%	+213.5%	0.052%
11/8/2023	Pathstone Family Office LLC	148,392	$58K	0.0%	+344.2%	0.055%
11/8/2023	Vanguard Personalized Indexing Management LLC	109,213	$42K	0.0%	N/A	0.041%
10/27/2023	Hennion & Walsh Asset Management Inc.	163,562	$64K	0.0%	-16.5%	0.061%
10/10/2023	Green Alpha Advisors LLC	570,049	$0.22M	0.2%	+212.7%	0.213%
9/21/2023	Barclays PLC	64,715	$29K	0.0%	-92.5%	0.024%
8/7/2023	Keystone Financial Group	106,397	$48K	0.0%	N/A	0.040%
7/24/2023	Allspring Global Investments Holdings LLC	66,536	$30K	0.0%	N/A	0.025%
7/18/2023	Allspring Global Investments Holdings LLC	66,536	$30K	0.0%	N/A	0.025%
7/6/2023	Green Alpha Advisors LLC	182,297	$81K	0.1%	+24.6%	0.069%
7/5/2023	Cedar Brook Financial Partners LLC	130,522	$58K	0.0%	+24.4%	0.050%
5/12/2023	Profund Advisors LLC	418,749	$0.34M	0.0%	N/A	0.161%
5/5/2023	Prime Capital Investment Advisors LLC	34,802	$29K	0.0%	N/A	0.013%
5/4/2023	Barclays PLC	858,782	$0.71M	0.0%	-36.6%	0.330%
5/4/2023	Mirae Asset Global Investments Co. Ltd.	92,434	$76K	0.0%	N/A	0.036%
5/3/2023	Beck Bode LLC	41,218	$34K	0.0%	+51.4%	0.016%
4/28/2023	SG Americas Securities LLC	96,073	$79K	0.0%	+714.3%	0.037%
4/18/2023	ETF Managers Group LLC	86,366	$71K	0.0%	+38.8%	0.033%
4/4/2023	Cedar Brook Financial Partners LLC	104,881	$86K	0.0%	+18.2%	0.040%
3/23/2023	ETF Managers Group LLC	62,201	$97K	0.0%	-15.5%	0.024%
3/23/2023	MetLife Investment Management LLC	96,883	$0.15M	0.0%	-18.5%	0.037%
2/14/2023	Alpine Global Management LLC	76,178	$0.12M	0.0%	N/A	0.031%
2/13/2023	GSA Capital Partners LLP	160,080	$0.25M	0.0%	N/A	0.064%
2/10/2023	Arlington Capital Management Inc.	28,070	$44K	0.0%	N/A	0.011%
2/10/2023	Moors & Cabot Inc.	11,350	$57K	0.0%	N/A	0.005%
2/9/2023	Citigroup Inc.	1,180,030	$1.84M	0.0%	-41.4%	0.473%
2/8/2023	Brainard Capital Management LLC	16,666	$26K	0.0%	N/A	0.007%
2/8/2023	Swiss National Bank	602,200	$0.94M	0.0%	+10.9%	0.241%
2/8/2023	Arizona State Retirement System	70,375	$0.11M	0.0%	+13.1%	0.028%
2/8/2023	Beck Bode LLC	27,226	$42K	0.0%	N/A	0.011%
2/7/2023	Keystone Financial Group	99,288	$0.16M	0.0%	+34.1%	0.040%
2/7/2023	Mitsubishi UFJ Kokusai Asset Management Co. Ltd.	118,000	$0.18M	0.0%	-7.8%	0.047%
2/7/2023	Moors & Cabot Inc.	11,350	$57K	0.0%	N/A	0.005%
2/6/2023	Daiwa Securities Group Inc.	32,186	$50K	0.0%	-20.1%	0.013%
2/6/2023	Greenwich Wealth Management LLC	18,700	$29K	0.0%	-39.9%	0.007%
2/1/2023	Zurcher Kantonalbank Zurich Cantonalbank	39,466	$62K	0.0%	+44.0%	0.016%
1/12/2023	Hennion & Walsh Asset Management Inc.	393,164	$0.61M	0.0%	+11.5%	0.158%
11/15/2022	Financial Advocates Investment Management	14,161	$0.63M	0.1%	N/A	0.006%
11/15/2022	Caxton Associates LP	130,728	$0.23M	0.0%	N/A	0.052%
11/14/2022	Point72 Hong Kong Ltd	24,515	$42K	0.0%	N/A	0.010%
11/14/2022	Cubist Systematic Strategies LLC	427,961	$0.74M	0.0%	N/A	0.172%
11/14/2022	MetLife Investment Management LLC	118,934	$0.21M	0.0%	+77.5%	0.048%
11/14/2022	Metropolitan Life Insurance Co NY	14,957	$26K	0.0%	+88.5%	0.006%
11/14/2022	E Fund Management Co. Ltd.	127,683	$0.22M	0.0%	-23.8%	0.051%
11/14/2022	Hennion & Walsh Asset Management Inc.	352,721	$0.61M	0.0%	-2.3%	0.141%
11/10/2022	WINTON GROUP Ltd	49,733	$86K	0.0%	-8.4%	0.020%
11/10/2022	Connor Clark & Lunn Investment Management Ltd.	28,143	$49K	0.0%	N/A	0.011%
11/10/2022	ExodusPoint Capital Management LP	53,544	$92K	0.0%	N/A	0.021%
11/10/2022	Tower Research Capital LLC TRC	129,084	$0.22M	0.0%	+101.8%	0.052%
11/9/2022	Amalgamated Bank	31,932	$55K	0.0%	+17.5%	0.013%
11/7/2022	Virtu Financial LLC	130,829	$0.23M	0.0%	+53.0%	0.052%
11/7/2022	Quantbot Technologies LP	134,457	$0.23M	0.0%	+100.8%	0.054%
11/7/2022	Arizona State Retirement System	62,242	$0.11M	0.0%	+9.2%	0.025%
11/7/2022	ProShare Advisors LLC	48,226	$83K	0.0%	+13.4%	0.019%
11/3/2022	Teacher Retirement System of Texas	74,737	$0.13M	0.0%	+119.8%	0.030%
11/3/2022	Barclays PLC	1,156,481	$2M	0.0%	+10,382.0%	0.464%
11/2/2022	Daiwa Securities Group Inc.	40,273	$69K	0.0%	-22.0%	0.016%
11/1/2022	Great West Life Assurance Co. Can	16,726	$28K	0.0%	N/A	0.007%
10/31/2022	SG Americas Securities LLC	71,417	$0.12M	0.0%	-78.6%	0.029%
10/25/2022	Raymond James & Associates	19,157	$33K	0.0%	-32.9%	0.008%
10/14/2022	Green Alpha Advisors LLC	147,380	$0.25M	0.2%	+12.8%	0.059%
8/13/2022	Virtu Financial LLC	85,504	$0.15M	0.0%	N/A	0.034%
8/12/2022	Virtus ETF Advisers LLC	72,014	$0.13M	0.0%	+174.4%	0.031%
8/12/2022	Rafferty Asset Management LLC	2,071,803	$3.58M	0.0%	+4.6%	0.831%
8/10/2022	WINTON GROUP Ltd	54,307	$94K	0.0%	+32.0%	0.024%
8/9/2022	TIAA FSB	14,348	$25K	0.0%	N/A	0.006%
8/8/2022	Eqis Capital Management Inc.	29,987	$52K	0.0%	+28.3%	0.013%
8/8/2022	Keebeck Alpha LP	16,756	$29K	0.0%	N/A	0.007%
8/4/2022	Mitsubishi UFJ Kokusai Asset Management Co. Ltd.	126,500	$0.22M	0.0%	+182.1%	0.055%
8/1/2022	ProShare Advisors LLC	42,530	$74K	0.0%	-29.7%	0.019%

Data available starting January 2016

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Today's Range

Now: $4.06

$3.97

$4.24

50 Day Range

MA: $5.61

$3.97

$6.82

52 Week Range

Now: $4.06

$3.85

$14.75

Volume

565,158 shs

Average Volume

404,986 shs

Market Capitalization

$105.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83

Who are the company insiders with the largest holdings of Inovio Pharmaceuticals?: Inovio Pharmaceuticals' top insider shareholders include:
David B Weiner (Director)
Learn More about top insider investors at Inovio Pharmaceuticals.
Who are the major institutional investors of Inovio Pharmaceuticals?: Inovio Pharmaceuticals' top institutional shareholders include:
Geode Capital Management LLC — 2.39%
State Street Corp — 1.89%
Wellington Management Group LLP — 0.25%
Barclays PLC — 0.13%
Barclays PLC — 0.13%
FMR LLC — 0.11%
Learn More about top institutional investors of Inovio Pharmaceuticals stock.
Which institutional investors are selling Inovio Pharmaceuticals stock?: Within the previous quarter, INO stock was sold by these institutional investors:
Wolverine Trading LLC
Jane Street Group LLC
Which institutional investors are buying Inovio Pharmaceuticals stock?: Within the last quarter, INO stock was bought by institutional investors including:
Wellington Management Group LLP
State Street Corp
Geode Capital Management LLC
Barclays PLC
Barclays PLC
FMR LLC
Atom Investors LP
SG Americas Securities LLC